Do you want to remove all your recent searches?

All recent searches will be deleted

New antibiotic for C. diff bug

8 years ago124 views

multivu

MultiVu

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company’s novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection (CDI). The Phase 3 trial showed that fidaxomicin significantly reduced recurrence rates and increased global cure rates when compared to vancomycin, the only treatment approved by the U.S. Food and Drug Administration for CDI. The article titled, "Fidaxomicin versus Vancomycin for Clostridium difficile Infection,” appears in the February 3, 2011 issue of The New England Journal of Medicine. To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/47526/

Report this video

Select an issue

  • Sexual content
  • Violent content
  • Defamation or Hateful content
  • Fake news story

Embed the video

New antibiotic for C. diff bug
Autoplay
<iframe frameborder="0" width="480" height="270" src="https://www.dailymotion.com/embed/video/xgvnon" allowfullscreen allow="autoplay"></iframe>
Add the video to your site with the embed code above

Report this video

Select an issue

  • Sexual content
  • Violent content
  • Defamation or Hateful content
  • Fake news story

Embed the video

New antibiotic for C. diff bug
Autoplay
<iframe frameborder="0" width="480" height="270" src="https://www.dailymotion.com/embed/video/xgvnon" allowfullscreen allow="autoplay"></iframe>
Add the video to your site with the embed code above